Clinical trial
Bexarotene Treatment in Schizophrenia
NCT00141947 · Beersheva Mental Health Center, Other · Unknown status
Key facts
| NCT number | NCT00141947 |
|---|---|
| Title | Bexarotene Treatment in Schizophrenia |
| Official title | Safety and Efficacy of Add-On Oral Bexarotene to Antipsychotic Treatment in Schizophrenia Patients: An Open Label Trial |
| Lead sponsor | Beersheva Mental Health Center, Other |
| Collaborators | Stanley Medical Research Institute |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | bexarotene (Targretin) |
| Enrollment | 15 |
| Start date | Sep 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Sep 2, 2005 |
| Last update posted | Jul 24, 2013 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: